Health
TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY® Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
TOKYO & BASKING RIDGE, N.J., January 13, 2026--The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating DATROWAY® (datopotamab deruxtecan) compared to docetaxel in patients with TROP2 NMR positive locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) without actionable genomic alterations previously treated with immunotherapy and platinum-based chemotherapy.
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":474,"url":"https://media.zenfs.com/en/business-wire.com/b0d58405abdc352de8b6d0c698682bee"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/DgivqREfeTKZRKqSt1AuYg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk0ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/b0d58405abdc352de8b6d0c698682bee","width":480,"height":474}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"First phase 3 trial to prospectively enroll patients with tumors that test positively for TROP2 NMR, a novel computational pathology biomarker to identify those most likely to benefit from Daiichi Sankyo and AstraZeneca’s DATROWAY","length":230,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":230,"olType":false},{"type":"text","content":"TOKYO & BASKING RIDGE, N.J., January 13, 2026--(BUSINESS WIRE)--The first patient has been dosed in the TROPION-Lung17 phase 3 trial evaluating DATROWAY® (datopotamab deruxtecan) compared to docetaxel in patients with TROP2 NMR positive locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) without actionable genomic alterations previously treated with immunotherapy and platinum-based chemotherapy.","length":428,"tagName":"p"},{"type":"text","content":"DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN).","length":231,"tagName":"p"},{"type":"text","content":"The current standard first-line treatment for advanced NSCLC without actionable genomic alterations is immunotherapy with or without platinum-based chemotherapy.1 However, most patients will eventually experience disease progression and traditional chemotherapy remains the current standard of care in the second-line and beyond settings.2,3,4,5 While TROP2 is a protein broadly expressed on the surface and inside of NSCLC cells, there is no established predictive biomarker that can identify patients who may benefit from a TROP2 directed antibody drug conjugate.6,7 TROPION-Lung17 is the first phase 3 clinical trial to prospectively enroll patients with tumors that test positively for TROP2...